Quick Takeaways:
- Antech announced a new peer-reviewed study in JAVMA evaluating its Accuplex test against IDEXX’s SNAP 4Dx Plus for tick-borne pathogen screening in dogs, finding comparable performance for Anaplasma spp.
- Accuplex detected 94% of Ehrlichia spp.-positive samples versus 58% for SNAP 4Dx Plus against the IFA reference standard (P<.001). Both tests showed over 90% sensitivity for Anaplasma and over 95% specificity.
- The findings support Accuplex as an option for routine vector-borne disease screening in dogs, offering greater sensitivity for Ehrlichia antibody detection in this study. Researchers from Antech, Colorado State University, and UT Medical Branch co-authored the study.
Why It Matters?
Antech’s peer-reviewed Accuplex findings could strengthen its competitive position in canine vector-borne disease diagnostics, particularly for Ehrlichia antibody detection, where it outperformed IDEXX’s SNAP 4Dx Plus in this study. Independent validation may support veterinary adoption, though broader clinical evidence and real-world performance will influence its impact on IDEXX’s established market position.
Source: Businesswire
